These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15141344)

  • 1. Mycophenolate mofetil as an alternative to cyclosporine in post renal transplant thrombocytopenia.
    Phadke K; Bagirath A
    Pediatr Nephrol; 2004 Jul; 19(7):822-3. PubMed ID: 15141344
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil in cyclosporine-associated nephrotoxicity.
    Ducloux D; Fournier V; Bresson-Vautrin C; Rebibou JM; Saint-Hillier Y; Chalopin JM
    Transplant Proc; 1998 Sep; 30(6):2825-7. PubMed ID: 9745583
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome.
    Agarwal DK; Gulati S; Mehta A; Kumar A; Sharma RK; Mehta B; Gupta A; Gupta RK
    Nephrol Dial Transplant; 2000 Dec; 15(12):2064-5. PubMed ID: 11096161
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of mycophenolate mofetil in patients with chronic cyclosporine nephrotoxicity.
    Wombolt DG; McCune TR; Stewart M
    Transplant Proc; 1998 Jun; 30(4):1194. PubMed ID: 9636483
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of presumptive primary immune-mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs.
    Cummings FO; Rizzo SA
    J Small Anim Pract; 2017 Feb; 58(2):96-102. PubMed ID: 28160307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate mofetil on progression of renal disease.
    Weir MR; Fink JC; Hanes DS; Gardner J; Klassen DK; Cangro C; Schweitzer E; Bartlett ST
    Transplant Proc; 1999; 31(1-2):1286-7. PubMed ID: 10083574
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of the allopurinol-mycophenolate mofetil combination in the treatment of hyperuricemia of kidney transplant recipients.
    Navascués RA; Gómez E; Rodriguez M; Laures AS; Baltar J; Grande JA
    Nephron; 2002 May; 91(1):173-4. PubMed ID: 12021539
    [No Abstract]   [Full Text] [Related]  

  • 9. Contribution of mycophenolate mofetil after withdrawal of cyclosporine to toxicity in kidney transplantation.
    Hazzan M; Bourdon F; Dracon M; Lelièvre G; Noël C
    Transplant Proc; 1998 Sep; 30(6):2809-10. PubMed ID: 9745575
    [No Abstract]   [Full Text] [Related]  

  • 10. Mycophenolate mofetil in cyclosporin-associated thrombotic microangiopathy.
    Lecornu-Heuze L; Ducloux D; Rebibou JM; Martin L; Billerey C; Chalopin JM
    Nephrol Dial Transplant; 1998 Dec; 13(12):3212-3. PubMed ID: 9870494
    [No Abstract]   [Full Text] [Related]  

  • 11. Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.
    Sanchez V; Delgado JF; Morales JM; Tello R; Gómez MA; Escribano P; de la Cámara AG; de la Calzada CS
    Transplant Proc; 2004 Nov; 36(9):2823-5. PubMed ID: 15621159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients.
    Johnson DW; Nicol DL; Preston JM; Brown AM; Hawley CM; Campbell SB; Wall D; Griffin AD; Isbel NM
    Transplantation; 2003 Aug; 76(3):619. PubMed ID: 12923455
    [No Abstract]   [Full Text] [Related]  

  • 13. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead.
    Hussein MM; Mooij JM; Roujouleh HM
    Nephrol Dial Transplant; 2000 Jul; 15(7):1103-4. PubMed ID: 10862670
    [No Abstract]   [Full Text] [Related]  

  • 14. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
    Dvorak CC; Callard E; Agarwal R
    Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
    [No Abstract]   [Full Text] [Related]  

  • 16. A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients.
    Picard N; Prémaud A; Rousseau A; Le Meur Y; Marquet P
    Br J Clin Pharmacol; 2006 Oct; 62(4):477-84. PubMed ID: 16995869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of mycophenolate mofetil to treat severe chronic urticaria in a patient intolerant to ciclosporin.
    Raghavendran RR; Humphreys F; Kaur MR
    Clin Exp Dermatol; 2014 Jan; 39(1):68-9. PubMed ID: 23692555
    [No Abstract]   [Full Text] [Related]  

  • 18. Haemolytic-uraemic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil.
    McGregor DO; Robson RA; Lynn KL
    Nephron; 1998 Nov; 80(3):365-6. PubMed ID: 9807054
    [No Abstract]   [Full Text] [Related]  

  • 19. [Mycophenolate mofetil].
    Abramowicz D; Broeders N; Wissing M; Sternon J
    Rev Med Brux; 1998 Jun; 19(3):139-43. PubMed ID: 9697397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of mycophenolate mofetil in patients with a transplanted kidney and cyclosporin nephrotoxicity].
    Hrvacević R; Ignjatović Lj; Vavić N; Dimitrijević J; Drasković-Pavlović B; Dujić A; Elaković D; Kronja G; Marić M
    Vojnosanit Pregl; 2001; 58(2):157-60. PubMed ID: 11475669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.